Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Richter

Showing results (531-540 of 546) with videos related to

Pageof 55
Sort By:
The Lancet. Infectious Diseases|August 13, 2022
Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adultsSaskia C van der Boor, Merel J Smit, Stijn W van Beek, et al.
Nature Structural & Molecular Biology|May 28, 2013
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120Leopold Kong, Jeong Hyun Lee, Katie J Doores, et al.
Biomolecular NMR Assignments|August 18, 2020
<sup>1</sup>H, <sup>13</sup>C, and <sup>15</sup>N backbone chemical shift assignments of the apo and the ADP-ribose bound forms of the macrodomain of SARS-CoV-2 non-structural protein 3bF Cantini, L Banci, N Altincekic, et al.
Immunity|August 17, 2022
Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responsesBrandon McLeod, Moustafa T Mabrouk, Kazutoyo Miura, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 21, 2015
Acute hepatitis C in the Netherlands: characteristics of the epidemic in 2014S J Hullegie, G E L van den Berk, E M S Leyten, et al.
Immunity|February 15, 2023
Highly potent, naturally acquired human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to mosquitoesAmanda Fabra-García, Sophia Hailemariam, Roos M de Jong, et al.
Nature Medicine|January 3, 2024
A candidate antibody drug for prevention of malariaKatherine L Williams, Steve Guerrero, Yevel Flores-Garcia, et al.
Plos One|October 18, 2011
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adultsMartha Sedegah, Cindy Tamminga, Shannon McGrath, et al.
Plos One|October 18, 2011
Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP componentCindy Tamminga, Martha Sedegah, David Regis, et al.
Nature Communications|June 7, 2024
Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complexBarnabas G Williams, Lloyd D W King, David Pulido, et al.
Pageof 55

Showing results (531-540 of 546) with videos related to

Sort By:
Pageof 55
The Lancet. Infectious Diseases|August 13, 2022
Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adultsSaskia C van der Boor, Merel J Smit, Stijn W van Beek, et al.
Nature Structural & Molecular Biology|May 28, 2013
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120Leopold Kong, Jeong Hyun Lee, Katie J Doores, et al.
Biomolecular NMR Assignments|August 18, 2020
<sup>1</sup>H, <sup>13</sup>C, and <sup>15</sup>N backbone chemical shift assignments of the apo and the ADP-ribose bound forms of the macrodomain of SARS-CoV-2 non-structural protein 3bF Cantini, L Banci, N Altincekic, et al.
Immunity|August 17, 2022
Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responsesBrandon McLeod, Moustafa T Mabrouk, Kazutoyo Miura, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 21, 2015
Acute hepatitis C in the Netherlands: characteristics of the epidemic in 2014S J Hullegie, G E L van den Berk, E M S Leyten, et al.
Immunity|February 15, 2023
Highly potent, naturally acquired human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to mosquitoesAmanda Fabra-García, Sophia Hailemariam, Roos M de Jong, et al.
Nature Medicine|January 3, 2024
A candidate antibody drug for prevention of malariaKatherine L Williams, Steve Guerrero, Yevel Flores-Garcia, et al.
Plos One|October 18, 2011
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adultsMartha Sedegah, Cindy Tamminga, Shannon McGrath, et al.
Plos One|October 18, 2011
Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP componentCindy Tamminga, Martha Sedegah, David Regis, et al.
Nature Communications|June 7, 2024
Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complexBarnabas G Williams, Lloyd D W King, David Pulido, et al.
Pageof 55